Academic Cancer Center Phase I Program Development

Arthur E. Frankel; Keith T. Flaherty; George J. Weiner; Robert Chen; Nilofer S. Azad; Michael J. Pishvaian; John A. Thompson; Matthew H. Taylor; Daruka Mahadevan; A. Craig Lockhart; Ulka N. Vaishampayan; Jordan D. Berlin; David C. Smith; John Sarantopoulos; Matthew Riese; Mansoor N. Saleh; Chul Ahn; Eugene P. Frenkel

doi:10.1634/theoncologist.2016-0409

Back

Academic Cancer Center Phase I Program Development

Journal article

Open access

Peer reviewed

Academic Cancer Center Phase I Program Development

Arthur E. Frankel, Keith T. Flaherty, George J. Weiner, Robert Chen, Nilofer S. Azad, Michael J. Pishvaian, John A. Thompson, Matthew H. Taylor, Daruka Mahadevan, A. Craig Lockhart, …

The oncologist (Dayton, Ohio), Vol.22(4), pp.369-374

01/01/2017

DOI: 10.1634/theoncologist.2016-0409

PMCID: PMC5388388

PMID: 28314841

Files and links (1)

url

https://doi.org/10.1634/theoncologist.2016-0409View

Published (Version of record) Open Access

Abstract

Multiple factors critical to the effectiveness of academic phase I cancer programs were assessed among 16 academic centers in the U.S. Successful cancer centers were defined as having broad phase I and I/II clinical trial portfolios, multiple investigator-initiated studies, and correlative science. The most significant elements were institutional philanthropic support, experienced clinical research managers, robust institutional basic research, institutional administrative efforts to reduce bureaucratic regulatory delays, phase I navigators to inform patients and physicians of new studies, and a large cancer center patient base. New programs may benefit from a separate stand-alone operation, but mature phase I programs work well when many of the activities are transferred to disease-oriented teams. The metrics may be useful as a rubric for new and established academic phase I programs.

Life Sciences & Biomedicine

Oncology

Science & Technology

Details

Title: Subtitle: Academic Cancer Center Phase I Program Development
Creators: Arthur E. Frankel - The University of Texas Southwestern Medical Center
Keith T. Flaherty - Harvard University
George J. Weiner - University of Iowa
Robert Chen - City Of Hope National Medical Center
Nilofer S. Azad - Johns Hopkins University
Michael J. Pishvaian - Georgetown University
John A. Thompson - Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA
Matthew H. Taylor - University of Portland
Daruka Mahadevan - University of Arizona
A. Craig Lockhart - Washington University in St. Louis
Ulka N. Vaishampayan - Wayne State University
Jordan D. Berlin - Vanderbilt University
David C. Smith - University of Michigan–Ann Arbor
John Sarantopoulos - The University of Texas Health Science Center at San Antonio
Matthew Riese - Medical College of Wisconsin
Mansoor N. Saleh - University of Alabama at Birmingham
Chul Ahn - The University of Texas Southwestern Medical Center
Eugene P. Frenkel - The University of Texas Southwestern Medical Center
Resource Type: Journal article
Publication Details: The oncologist (Dayton, Ohio), Vol.22(4), pp.369-374
Publisher: Wiley
DOI: 10.1634/theoncologist.2016-0409
PMID: 28314841
PMCID: PMC5388388
ISSN: 1083-7159
eISSN: 1549-490X
Number of pages: 6
Grant note: T. Boone Pickens Fund for Cancer Research P30CA086862 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Language: English
Date published: 01/01/2017
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
Record Identifier: 9984359778202771

Metrics

21 Record Views